Biotechnology Value Fund L P's Form 4 filing
Repare Therapeutics Inc. (RPTX) · filed Nov 17, 2023
- Accession no.
- 0000921895-23-002669
- Filed
- Nov 17, 2023, 4:54 PM ET
- Trade date
- Nov 15-16, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 0 derivative transactions. Open-market purchases total $6.25M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Biotechnology Value Fund L PCIK 0000918923 | 10% Owner |
| BVF Partners L PCIK 0001055947 | 10% Owner |
| BVF IncCIK 0001056807 | 10% Owner |
| Biotechnology Value Fund II LPCIK 0001102444 | 10% Owner |
| Lampert Mark NCIK 0001233840 | 10% Owner |
| Biotechnology Value Trading Fund OS LPCIK 0001660683 | Other: See Explanation of Responses |
| BVF Partners OS Ltd.CIK 0001660684 | Other: See Explanation of Responses |
| BVF I GP LLCCIK 0001803805 | 10% Owner |
| BVF II GP LLCCIK 0001803806 | 10% Owner |
| BVF GP Holdings LLCCIK 0001803809 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 15, 2023 | Common Shares, no par value | PPurchaseAcquired | +493,337 | $5.00 | +$2,466,635.67 | 5,155,739 | Direct | |
| Nov 15, 2023 | Common Shares, no par value | PPurchaseAcquired | +390,507 | $5.00 | +$1,952,495.95 | 4,182,664 | Direct | |
| Nov 15, 2023 | Common Shares, no par value | PPurchaseAcquired | +47,712 | $5.00 | +$238,555.23 | 532,795 | Direct | |
| Nov 16, 2023 | Common Shares, no par value | PPurchaseAcquired | +153,693 | $5.38 | +$827,437 | 5,309,432 | Direct | |
| Nov 16, 2023 | Common Shares, no par value | PPurchaseAcquired | +125,909 | $5.38 | +$677,856.28 | 4,308,573 | Direct | |
| Nov 16, 2023 | Common Shares, no par value | PPurchaseAcquired | +16,143 | $5.38 | +$86,909.07 | 548,938 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.